A Musolino

Summary

Publications

  1. ncbi Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    J Clin Oncol 30:2362-8. 2012
  2. ncbi Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study
    Antonino Musolino
    Medical Oncology Unit and Cancer Registry of Parma Province, University Hospital of Parma, Parma, Italy
    Cancer 117:1837-46. 2011
  3. ncbi Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Parma, Italy
    Cancer 117:964-73. 2011
  4. ncbi Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Italy
    Tumori 96:24-7. 2010
  5. ncbi Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Parma, Italy
    Br J Haematol 145:84-6. 2009
  6. ncbi Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    J Clin Oncol 26:1789-96. 2008
  7. ncbi Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia
    A Musolino
    Medical Oncology Unit, University Hospital of Parma, Parma Italy
    Haematologica 92:e59-61. 2007
  8. ncbi BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Breast 16:280-92. 2007
  9. ncbi Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Tumori 91:505-12. 2005
  10. ncbi A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Breast Cancer Res Treat 91:203-5. 2005

Collaborators

Detail Information

Publications17

  1. ncbi Human epidermal growth factor receptor 2 status and interval breast cancer in a population-based cancer registry study
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    J Clin Oncol 30:2362-8. 2012
    ....
  2. ncbi Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study
    Antonino Musolino
    Medical Oncology Unit and Cancer Registry of Parma Province, University Hospital of Parma, Parma, Italy
    Cancer 117:1837-46. 2011
    ..Trastuzumab, which does not cross the blood-brain barrier, has been associated with this increased risk...
  3. ncbi Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Parma, Italy
    Cancer 117:964-73. 2011
    ....
  4. ncbi Accuracy and relative value of bone marrow aspiration in the detection of lymphoid infiltration in non-Hodgkin lymphoma
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Italy
    Tumori 96:24-7. 2010
    ..The present study evaluated the accuracy of bone marrow aspiration and the relative contributions of bone marrow aspiration and bone marrow biopsy in detecting bone marrow involvement by non-Hodgkin lymphomas...
  5. ncbi Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Parma, Italy
    Br J Haematol 145:84-6. 2009
    ..If fenofibate-related side effects occur, or a statin is required to control low-density lipoprotein-cholesterol, omega-3 fatty acids should be considered as a good alternative therapy to lower lipid levels during bexarotene treatment...
  6. ncbi Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    J Clin Oncol 26:1789-96. 2008
    ..In this study, we tested whether Fc gamma R polymorphisms are associated with clinical outcome of patients with breast cancer who received trastuzumab...
  7. ncbi Intracranial hematopoiesis in a patient with AIDS-related central nervous system lymphoma and severe pancytopenia
    A Musolino
    Medical Oncology Unit, University Hospital of Parma, Parma Italy
    Haematologica 92:e59-61. 2007
    ..Although rare, intracranial EMH should always be considered in the differential diagnosis of headache and other endocranial hypertension symptoms in patients with chronic bone marrow dysfunction...
  8. ncbi BRCA mutations, molecular markers, and clinical variables in early-onset breast cancer: a population-based study
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Breast 16:280-92. 2007
    ..Further studies on incident cases are necessary to define the independent prognostic significance of germline BRCA mutations...
  9. ncbi Molecular profile and clinical variables in BRCA1-positive breast cancers. A population-based study
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Tumori 91:505-12. 2005
    ..To evaluate the clinical features of breast cancer patients with genetic susceptibility to this disease and to investigate the contribution of BRCA1 germline mutations to the phenotype of these tumors...
  10. ncbi A breast cancer patient from Italy with germline mutations in both the BRCA1 and BRCA2 genes
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Via Gramsci 14, 43100 Parma, Italy
    Breast Cancer Res Treat 91:203-5. 2005
    ..The proband and her mother were diagnosed with early-onset breast cancer. No other relatives with breast and/or ovarian cancer were observed. The implications of this case in regard to genetic testing and counseling are substantial...
  11. ncbi [Appendiceal mucocele]
    N Kunin
    , , San Martin--Buenos Aires (Argentine
    J Chir (Paris) 140:46-7. 2003
  12. ncbi Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma
    Antonino Musolino
    Medical Oncology Unit, University Hospital of Parma, Parma, Italy
    Cancer 103:2109-17. 2005
    ..The current study was designed to assess the activity and safety of a novel combination therapy for patients with recurrent or refractory aggressive non-Hodgkin lymphoma (NHL)...
  13. ncbi Evaluation of HER-2/neu amplification and other biological markers as predictors of response to neoadjuvant anthracycline-based chemotherapy in primary breast cancer: the role of anthracycline dose intensity
    Cecilia Bozzetti
    Deparment of Medical Oncology, University Hospital, Parma, Italy
    Am J Clin Oncol 29:171-7. 2006
    ..We evaluated the contribution of HER-2/neu gene amplification and other biologic markers in predicting response to different doses of neoadjuvant anthracycline-based chemotherapy...
  14. ncbi p73 and p53 pathway in human breast cancers
    Cecilia Bozzetti
    J Clin Oncol 25:1451-3; author reply 1453-4. 2007
  15. ncbi Early detection of recurrences in the follow-up of primary breast cancer in an asymptomatic or symptomatic phase
    Maria Antonietta Perrone
    Medical Oncology Division, University Hospital, Parma
    Tumori 90:276-9. 2004
    ..The aim of the present study was to investigate the modality of detection of the first relapse in the asymptomatic vs the symptomatic state...
  16. ncbi Lung cancer in patients with chronic lymphocytic leukemia: does the HER-2 oncogene play a role?
    Antonino Musolino
    Lung Cancer 50:419-20. 2005
  17. ncbi Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy
    Francesca Negri
    Department of Medicine, Royal Marsden Hospital, Downs Road, Sutton, Surrey SM2 5PT, U.K
    Clin Colorectal Cancer 4:101-6. 2004
    ..Moreover, preoperative chemotherapy produced a high response rate, with no patients experiencing disease progression before surgery...